Beijing Green Bamboo Biotechnology

Beijing Green Bamboo Biotechnology is a clinical-stage biopharmaceutical company based in China, specializing in the development of innovative human vaccines and therapeutic biologics. The company focuses on addressing infectious diseases and autoimmune disorders through its proprietary recombinant protein technology platforms. Its lead product candidate, LZ901, is a recombinant shingles vaccine currently in Phase 3 clinical trials, designed to offer high efficacy and improved safety compared to existing options. Additionally, the company's pipeline includes biosimilars and bispecific antibodies targeting various cancers and inflammatory conditions. Green Bamboo Bio is committed to providing affordable, high-quality biopharmaceuticals to the global market.